scholarly journals Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review

2021 ◽  
Author(s):  
Bhagat Singh ◽  
Dheer Singh ◽  
Vinod Verma ◽  
Ramakant Yadav ◽  
Raj Kumar
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Therapeutic Target ◽  
Converting Enzyme ◽  
Potential Therapeutic Target ◽  
Angiotensin Converting Enzyme 2

scholarly journals ACE2 as a potential therapeutic target for pandemic COVID-19

RSC Advances ◽  
2020 ◽  
Vol 10 (65) ◽  
pp. 39808-39813
Author(s):  
Bhaswati Chatterjee ◽  
Suman S. Thakur
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Therapeutic Target ◽  
Converting Enzyme ◽  
Potential Therapeutic Target ◽  
Angiotensin Converting Enzyme 2

SARS-CoV-2 virus invades the host through angiotensin-converting enzyme 2 (ACE2) receptors by decreasing the ACE2 expression of the host.

scholarly journals High level production and characterization of truncated human angiotensin converting enzyme 2 in Nicotiana benthamiana plant as a potential therapeutic target in COVID-19

2021 ◽  
Author(s):  
Tarlan Mammedov ◽  
Irem Gurbuzaslan ◽  
Merve Ilgin ◽  
Damla Yuksel ◽  
Gunay Mammadova ◽  
...  
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Therapeutic Target ◽  
Nicotiana Benthamiana ◽  
Cost Effective ◽  
Benthamiana Plant ◽  
Converting Enzyme ◽  
Potential Therapeutic Target ◽  
Angiotensin Converting Enzyme 2 ◽  
High Level ◽  
Level Production

The COVID-19 pandemic, which is caused by SARS-CoV-2 has rapidly spread to more than 222 countries and has put global public health at high risk. The world urgently needs safe, a cost-effective SARS-CoV-2 coronavirus vaccine, therapeutic and antiviral drugs to combat the COVID-19. Angiotensin-converting enzyme 2 (ACE2), as a key receptor for SARS-CoV-2 infections, has been proposed as a potential therapeutic target in COVID-19 patients. In this study, we report high level production (about ~0.75 g /kg leaf biomass) of glycosylated and non-glycosylated forms of recombinant human truncated ACE2 in Nicotiana benthamiana plant. The plant produced recombinant human truncated ACE2s successfully bind to the SARC-CoV-2 spike protein, but deglycosylated ACE2 binds more strongly than the glycosylated counterpart. Importantly, both deglycosylated and glycosylated forms of AEC2 stable at elevated temperatures for prolonged periods and demonstrated strong anti-SARS-CoV-2 activity in vitro. The IC50 values of glycosylated and deglycosylated AEC2 were 0.4 and 24 μg/ml, respectively, for the pre-entry infection, when incubated with 100TCID50 of SARS-CoV-2. Thus, plant produced truncated ACE2s are promising cost-effective and safe candidate as a potential therapeutic targets in the treatment of COVID-19 patients.

Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases

2014 ◽  
Vol 92 (7) ◽  
pp. 558-565 ◽  
Author(s):  
Nirmal Parajuli ◽  
Tharmarajan Ramprasath ◽  
Vaibhav B. Patel ◽  
Wang Wang ◽  
Brendan Putko ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiovascular Diseases ◽  
Angiotensin Converting Enzyme ◽  
Therapeutic Target ◽  
Ang Ii ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2 ◽  
Heart Failure Patients ◽  
Positive Effects ◽  
Mas Receptor

Angiotensin-converting enzyme 2 (ACE2) is a monocarboxypeptidase that metabolizes several vasoactive peptides, including angiotensin II (Ang-II; a vasoconstrictive/proliferative peptide), which it converts to Ang-(1–7). Ang-(1–7) acts through the Mas receptor to mediate vasodilatory/antiproliferative actions. The renin–angiotensin system involving the ACE–Ang-II–Ang-II type-1 receptor (AT1R) axis is antagonized by the ACE2–Ang-(1–7)–Mas receptor axis. Loss of ACE2 enhances adverse remodeling and susceptibility to pressure and volume overload. Human recombinant ACE2 may act to suppress myocardial hypertrophy, fibrosis, inflammation, and diastolic dysfunction in heart failure patients. The ACE2–Ang-(1–7)–Mas axis may present a new therapeutic target for the treatment of heart failure patients. This review is mainly focused on the analysis of ACE2, including its influence and potentially positive effects, as well as the potential use of human recombinant ACE2 as a novel therapy for the treatment cardiovascular diseases, such as hypertension and heart failure.

Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by miR-421

2014 ◽  
Vol 127 (4) ◽  
pp. 243-249 ◽  
Author(s):  
Daniel W. Lambert ◽  
Louise A. Lambert ◽  
Nicola E. Clarke ◽  
Nigel M. Hooper ◽  
Karen E. Porter ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Transcriptional Regulation ◽  
Angiotensin Converting Enzyme ◽  
Therapeutic Target ◽  
Molecular Mechanisms ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2 ◽  
Post Transcriptional Regulation ◽  
Cardiac Myofibroblasts

The molecular mechanisms controlling the expression of ACE2, a critical regulator of cardiovascular homoeostasis, remain poorly defined. In the present study, we show that miR-421 regulates expression of ACE2 in cardiac myofibroblasts, identifying a possible new therapeutic target in cardiovascular disease.

scholarly journals Angiotensin-Converting Enzyme 2 as a Therapeutic Target for Heart Failure

2013 ◽  
Vol 11 (1) ◽  
pp. 58-63 ◽  
Author(s):  
Mohammed A. R. Chamsi-Pasha ◽  
Zhili Shao ◽  
W. H. Wilson Tang
Keyword(s):  
Heart Failure ◽  
Angiotensin Converting Enzyme ◽  
Therapeutic Target ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2

scholarly journals Evidence for Angiotensin-converting Enzyme 2 as a Therapeutic Target for the Prevention of Pulmonary Hypertension

2009 ◽  
Vol 179 (11) ◽  
pp. 1048-1054 ◽  
Author(s):  
Anderson J. Ferreira ◽  
Vinayak Shenoy ◽  
Yoriko Yamazato ◽  
Srinivas Sriramula ◽  
Joseph Francis ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Angiotensin Converting Enzyme ◽  
Therapeutic Target ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2

scholarly journals The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection

Pathogens ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 379
Author(s):  
Ahmed O. Kaseb ◽  
Yehia I. Mohamed ◽  
Alexandre E. Malek ◽  
Issam I. Raad ◽  
Lina Altameemi ◽  
...  
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Preventive Measures ◽  
Vulnerable Groups ◽  
The Novel ◽  
Converting Enzyme ◽  
Potential Therapeutic Target ◽  
Angiotensin Converting Enzyme 2 ◽  
Incidence And Mortality ◽  
Novel Coronavirus ◽  
The Impact

The novel coronavirus disease 2019 (COVID-19) pandemic has led to an unprecedented threat to the international community and raised major concerns in terms of public health safety. Although our current understanding of the complexity of COVID-19 pathogenesis remains limited, the infection is largely mediated by the interaction of viral spike protein and angiotensin-converting enzyme 2 (ACE2). The functional importance of ACE2 in different demographic and comorbid conditions may explain the significant variation in incidence and mortality of COVID-19 in vulnerable groups, and highlights its candidacy as a potential therapeutic target. We provide evidence supporting the idea that differences in incidence and severity of COVID-19 infection may be related to ACE2. Emerging data based on the prevalence and severity of COVID-19 among those with established high levels of ACE2 expression strongly support our hypothesis. Considering the burden of COVID-19 infection in these vulnerable groups and the impact of the potential therapeutic and preventive measures that would result from adopting ACE2-driven anti-viral strategies, our hypothesis may expedite global efforts to control the current COVID-19 pandemic.

Sign in / Sign up

Export Citation Format

Share Document